Table 1.
Patient’s characteristics.
| Vancomycin | Comparator | |||
|---|---|---|---|---|
| N | 5449 | 16.5% | 27,548 | 83.5% |
| Gender (female) | 2945 | 14.9% | 16,855 | 85.1% |
| Age (years) | 50.4 | ± 15.7 | 50.2 | ± 14.9 |
| Treatment duration | ||||
| ≤ 7 days | 4347 | 79.8% | 23,965 | 87.0% |
| 8–14 days | 871 | 16.0% | 2845 | 10.3% |
| ≥ 15 days | 231 | 4.2% | 738 | 2.7% |
| Infection coded (yes) | 2242 | 41.1% | 2785 | 10.1% |
| Surgical procedure (yes) | 1965 | 36.1% | 13,795 | 50.1% |
| Cardiovascular | 246 | 4.5% | 696 | 2.5% |
| Heart disease | 710 | 13.0% | 2210 | 8.0% |
| Diabetes | 1646 | 30.2% | 6567 | 23.8% |
| Hyperlipidemia | 2231 | 40.9% | 10,473 | 38.0% |
| Hypertension | 2905 | 53.3% | 13,251 | 48.1% |
| Cirrhosis | 256 | 4.7% | 1310 | 4.8% |
| Atrial fibrillation | 344 | 6.3% | 1241 | 4.5% |
| Hypercalemia | 79 | 1.5% | 446 | 1.6% |
| Lupus | 155 | 2.8% | 566 | 2.0% |
| Myeloma | 26 | 0.5% | 70 | 0.3% |
| Nephrolithiasis | 186 | 3.4% | 1051 | 3.8% |
| ACEi | 1003 | 18.4% | 4526 | 16.4% |
| ARB | 544 | 10.0% | 2660 | 9.7% |
| Statin | 1200 | 22.0% | 5499 | 20.0% |
| Beta-blocker | 988 | 18.2% | 4304 | 15.6% |
| Ca-channel-blocker | 651 | 12.0% | 3004 | 10.9% |
| Alpha-blocker | 215 | 3.9% | 894 | 3.2% |
| Thiazide | 707 | 13.0% | 3881 | 14.1% |
| K+-sparing diuretics | 244 | 4.5% | 1197 | 4.3% |
| Loop diuretic | 438 | 8.0% | 1387 | 5.0% |
| Niacin | 63 | 1.2% | 214 | 0.8% |
| Fibrate | 172 | 3.2% | 809 | 2.9% |
| Ezetimibe | 131 | 2.4% | 610 | 2.2% |
| OAK | 604 | 11.1% | 2315 | 8.4% |
| Aspirin | 51 | 0.9% | 200 | 0.7% |
| NSAID | 1511 | 27.7% | 7671 | 27.8% |
ACEi angiotensin converting enzyme inhibitor, ARB angiotensin receptor2 blocker, Ca channel-blocker, calcium channel blocker, OAK oral anticoagulation, NSAID non-steroidal anti-inflammatory drug.